Stoke Therapeutics Q1 revenue falls but beats estimates

Stoke Therapeutics

07/05/2026 21:41

Overview

Biotechnology firm's Q1 revenue fell yr/yr but beat analyst expectations

Company posted Q1 net loss of $50 mln, compared to net income a year ago

Q1 revenue decline reflects absence of prior-year Biogen license revenue

Outlook

Stoke expects Phase 3 EMPEROR study enrollment to complete in June 2026

Company anticipates EMPEROR study data readout in mid-2027 to support NDA submission

Company expects cash position to fund operations into 2028, including potential U.S. launch in early 2028

Result Drivers

REVENUE DECLINE DRIVER - Q1 revenue decrease primarily due to absence of prior-year $150.8 mln Biogen license revenue recognition

HIGHER R&D AND SG&A EXPENSES - Increased research, development and administrative costs driven by advancement of zorevunersen and launch readiness

Company press release: ID:nBw6Cr3RMa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$6.23 mln
$5.88 mln (10 Analysts)
Q1 EPS
-$0.79
Q1 Net Income
-$50.003 mln
Q1 Operating Expenses
$59.65 mln
Q1 Operating Income
-$53.42 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Stoke Therapeutics Inc is $40.00, about 20.2% above its May 6 closing price of $33.28

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)